ERBB2 and neoplasm: Anti-HER2 single domain antibodies and nanobodies have been evaluated, with iso-[211At]At-SAGMB-5F7 demonstrating high intracellular trapping of radioactivity and greater than 10:1 tumor-to-normal organ ratios except for the kidneys and lungs by 2 h post-injection [104].